Clinical and Economic Consequences of Failure of Initial Antibiotic Therapy for Hospitalized Patients With Complicated Skin and Skin-Structure Infections

Objective. To estimate the consequences of failure of initial antibiotic therapy for patients with complicated skin and skin-structure infections. Design. Retrospective cohort study. Setting. Large US multihospital database. Patients. We identified a total of 47,219 patients (age 18 years or older) who were admitted to the hospital for complicated skin and skin-structure infections from April 1, 2003, through March 31, 2004, and who received intravenous antibiotics during the first 2 hospital-days (ie, initial antibiotic therapy). Failure of therapy was defined as drainage, debridement, or receipt of other intravenous antibiotics at any subsequent time (except for changes to narrower-spectrum agents or any therapy change immediately before discharge). Predictors of failure of antibiotic therapy and mortality were examined using multivariate logistic regression. Analysis of covariance was used to estimate the impact of treatment failure on duration of intravenous antibiotic therapy, length of stay, and total inpatient charges. Results. For 10,782 admitted patients (22.8%), there was evidence of failure of initial antibiotic therapy. In multivariate analyses, treatment failure was associated with receipt of vasoactive medications during the first 2 hospital-days (odds ratio [OR], 1.66 [95% confidence interval {CI}, 1.19-2.31]), initiation of antibiotic therapy in the intensive care unit (OR, 1.53 [95% CI, 1.28-1.84]), and the patient's Charlson comorbidity index (OR per 1-point increase, 1.06 [95% CI, 1.04-1.08]); treatment failure was also was associated with a 3-fold increase in mortality (OR, 2.91 [95% CI, 2.34-3.62]). Compared with patients for whom initial treatment was successful, patients who experienced treatment failure received intravenous antibiotic therapy for a mean of 5.7 additional days, were hospitalized for a mean of 5.4 additional days, and incurred a mean of $5,285 (in 2003 dollars) in additional inpatient charges (all P <.01). Conclusion. Failure of initial antibiotic therapy in the treatment of complicated skin and skin-structure infections is associated with significantly worse clinical and economic outcomes.

[1]  Ronald N. Jones,et al.  Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). , 2007, Diagnostic microbiology and infectious disease.

[2]  Patchen Dellinger,et al.  Practice guidelines for the diagnosis and management of skin and soft-tissue infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Nicolau,et al.  Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. , 2005, Surgical infections.

[4]  M. M. van der Eerden,et al.  Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study , 2005, Thorax.

[5]  J. Griffith,et al.  Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[6]  ICU-Acquired Pneumonia Study Group,et al.  Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit , 1996, Intensive Care Medicine.

[7]  S. Sen,et al.  Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[8]  Susan K. Johnson,et al.  Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. , 2003, JAMA.

[9]  D. Nathwani Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? , 2003, The Journal of antimicrobial chemotherapy.

[10]  R. Wise Maximizing efficacy and reducing the emergence of resistance. , 2003, The Journal of antimicrobial chemotherapy.

[11]  S. Wilson,et al.  A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. , 2003, American journal of surgery.

[12]  Ronald N. Jones,et al.  Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). , 2003, Diagnostic microbiology and infectious disease.

[13]  R. Willke,et al.  Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. , 2003, Surgical infections.

[14]  F. Fagnani,et al.  Cost of Care for Inpatients with Community-Acquired Intra-Abdominal Infections , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  D. Talan,et al.  Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  G. Woods,et al.  Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  R. Nichols,et al.  Clinical presentations of soft-tissue infections and surgical site infections. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  H. Dupont,et al.  Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia , 2001, Intensive Care Medicine.

[19]  A. Torres,et al.  Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. , 2000, American journal of respiratory and critical care medicine.

[20]  R. Nichols,et al.  Optimal treatment of complicated skin and skin structure infections. , 1999, The Journal of antimicrobial chemotherapy.

[21]  M. Pfaller,et al.  Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). , 1999, Diagnostic microbiology and infectious disease.

[22]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[23]  H. G. Deery Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. , 1998, Infectious disease clinics of North America.

[24]  Ronald N. Jones,et al.  Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) , 1998, Antimicrobial Agents and Chemotherapy.

[25]  M. Kollef,et al.  The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. , 1998, Chest.

[26]  M. Niederman,et al.  Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. , 1998, American journal of respiratory and critical care medicine.

[27]  M. Rué,et al.  Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. , 1997, Critical care medicine.

[28]  M. Niederman,et al.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. , 1997, Chest.

[29]  D. Talan,et al.  Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  J. Boyce Methicillin-Resistant Staphylococcus aureus in Hospitals and Long-Term Care Facilities: Microbiology, Epidemiology, and Preventive Measures , 1992, Infection Control &#x0026; Hospital Epidemiology.

[31]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[32]  R. Milne,et al.  Antibiotic treatment for surgical peritonitis. , 1991, Annals of surgery.

[33]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[34]  N. Duan Smearing Estimate: A Nonparametric Retransformation Method , 1983 .